Literature DB >> 10804301

[Oral terbinafine-induced plantar pustular psoriasis].

T Le Guyadec1, P Saint-Blancard, S Bosonnet, R Le Vagueresse, G Lanternier.   

Abstract

BACKGROUND: Cutaneous reactions may occur in patients receiving terbinafine therapy, mainly rash and urticaria. More exceptionally, development of psoriasis has been described. We describe the development of plantar pustular psoriasis in a patient who took oral terbinafine. CASE REPORT: A 70-year-old man, without previously known history of psoriasis, was treated with terbinafine, 250 mg/day, for onychomycosis. Ten days later, a plantar pustular psoriasis appeared. The psoriasis cleared up after discontinuation of terbinafine and institution of antipsoriatic therapy. DISCUSSION: Terbinafine is an antifungal agent widely use in the treatment of onychomycosis. A skin reaction occurs in 3 p. 100 of patients. Only 24 cases of flare-up of previous psoriasis or psoriasis de novo after terbinafine have been described. The psoriasis generally clears after discontinuation of terbinafine. So, terbinafine is perhaps not the best first line therapy for onychomycosis in patients with psoriasis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10804301

Source DB:  PubMed          Journal:  Ann Dermatol Venereol        ISSN: 0151-9638            Impact factor:   0.777


  3 in total

Review 1.  [Terbinafine : Drug-induced lupus erythematodes and triggering of psoriatic skin lesions].

Authors:  P Mayser
Journal:  Hautarzt       Date:  2016-09       Impact factor: 0.751

2.  [Terbinafine-induced subacute cutaneous lupus erythematosus. Case report and review of the literature].

Authors:  T Matthes; M Hagedorn
Journal:  Hautarzt       Date:  2004-07       Impact factor: 0.751

3.  Triggering drug use in patients with psoriasis: an investigative report from Turkey.

Authors:  Zerrin Ogretmen; Ulku Askin; Meliha Merve Hiz; Sibel Cevizci
Journal:  Postepy Dermatol Alergol       Date:  2014-10-22       Impact factor: 1.837

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.